Nirsevimab in the Prevention of Respiratory Syncytial Virus Lower Respiratory Tract Disease: A Profile of Its Use

• 2023

  Log in to bookmark this resource.

  Log in
• Matt Shirley
DOI: https://dx.doi.org/10.1007/s40267-023-01039-4

---

Access Resources

• Journal ArticleEN
• Ask aRCie About This Resource

About

This article discusses the use of Nirsevimab (Beyfortus™), a long-acting monoclonal antibody targeting the respiratory syncytial virus (RSV) fusion protein, in preventing RSV lower respiratory tract disease. Nirsevimab is the first prophylactic monoclonal antibody licensed for use in all infants during their first RSV season, offering valuable protection against severe RSV disease in children. Clinical trial data shows that a single dose of nirsevimab effectively reduces the incidence of medically attended RSV lower respiratory tract disease in infants for at least 150 days. The extended serum half-life of nirsevimab provides protection throughout a typical RSV season, making it a significant advancement in RSV prevention.

---

Tags

Focus Area: Infectious Disease

Audience: Physicians

Emergency Management Stage: Preparedness (Prevention / Protection)

Bundles: Nirsevimab Library

Keywords: Antibodies, Monoclonal; Child, Preschool; Clinical Trials as Topic; Infant; Injections, Intramuscular; Pharmacokinetics; Respiratory Syncytial Virus Infections; Vaccines, Synthetic; Respiratory Syncytial Virus, Human

Institutions: Springer Nature

---

More like this

Antibody Therapies Set to Transform Respiratory Syncytial Virus Prevention for Babies 2023 · Springer Nature Oral Rehydration, Emergency Physicians, and Practice Parameters: A National Survey 2002 · Children's Hospital at Montefiore "Med-X": A Medical Examiner Surveillance Model for Bioterrorism and Infectious Disease Mortality 2007 · University of New Mexico

---

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

---